CNAT


Conatus (CNAT) Stock Price Could Hit Zero

Did an iceberg just wallop into Conatus (CNAT) stock? This biotech company’s shares plunged yesterday at breakneck speed of almost 70%.

Conatus Pharmaceuticals (CNAT) Stock Crashes After Trial Data Misses the Mark

Conatus Pharmaceuticals Inc. (CNAT) stock fell over 50% today amid disappointing results for the company’s 2b ENCORE-PH clinical trial in NASH cirrhosis.

Conatus Pharmaceuticals (CNAT): Analyst Is Putting Pen to Paper to Determine the Impact of Emricasan’s Setback

Nothing can kill a drug maker’s stock price like a failed clinical trial. Just take a look at the disaster that’s befallen Conatus …

Conatus Pharmaceuticals (CNAT): Oppenheimer Advises Investors to Wait for the Next Catalyst

Today, Conatus Pharmaceuticals (NASDAQ:CNAT) share price took a hit on the announcement that the drug maker’s POLT-HCV-SVR proof-of-concept clinical trial, in liver transplant patients …

What Spooked Conatus Pharmaceuticals (CNAT) Investors This Evening

Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. A lottery ticket, however, costs only …

Conatus Pharmaceuticals Inc (CNAT): Analyst Looks Forward to “Large Catalysts” Lying Ahead

Oppenheimer’s Jay Olson is optimistic about CNAT’s upside potential with the forthcoming topline data from the Phase 2 POLT study.

Oppenheimer Has a New Play for Biotech Fans: Conatus Pharmaceuticals Inc (CNAT)

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 17% …

H.C. Wainwright Bullish on Conatus Pharmaceuticals Inc (CNAT) on Back of Orphan Drug Designation for IDN-7314

On Monday, Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced that the FDA has granted Orphan Drug Designation to the company’s drug candidate IDN-7314, for the treatment …

Stock Update (NASDAQ:CNAT): Conatus Pharmaceuticals Inc Announces Exclusive Worldwide Option, Collaboration and License Agreement for Emricasan

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced it has entered into an exclusive option, collaboration and license agreement for the global development and commercialization of …

Stock Update (NASDAQ:CNAT): Conatus Pharmaceuticals Inc Announces Acceptance of Emricasan Abstracts for AASLD Annual Meeting

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced that abstracts for four posters — two addressing clinical results and two addressing preclinical results with the company’s …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts